Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

X
Trial Profile

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belantamab mafodotin (Primary) ; Belumosudil (Primary) ; Dexamethasone (Primary) ; Evorpacept (Primary) ; Isatuximab (Primary) ; Pegenzileukin (Primary) ; SAR 439459 (Primary) ; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
  • Most Recent Events

    • 24 Apr 2024 Planned number of patients changed from 197 to 229.
    • 30 Nov 2023 Planned End Date changed from 24 Nov 2028 to 2 Dec 2027.
    • 30 Nov 2023 Planned primary completion date changed from 24 Nov 2028 to 2 Dec 2027.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top